Comparative between Pfizer and SinoPharm Vaccinated Production Antibody

Muhammad Razouq Saleh[1], Osama Nadhom Nijris[2], Nahla Ghanim Abdul majeed[3]

1,2Department of pathological analysis, College of Applied Science, University of Samarra/Iraq

3 Department of Immunology, National Center for Teaching Laboratories, Medical City, Ministry of Health and Environment/Iraq

Email: us4200301013@uosamarra.edu.iq

Abstract

Vaccines against SARS-CoV-2 stimulate immune responses through a variety of methods, This research aims to examine the values of particular antibodies (IgG) in people who have been vaccinated against the disease in Pfizer-BioNTech SARS-CoV-2 or the Other SARS-CoV-2 vaccine or the SinoPharm-BBIBP-CorV vaccine, Participants in this future-looking observational studies iraqi adults vaccination received in two separate doses, 3 weeks apart, vaccination with any of the two vaccinations described above, After a delay of 8 weeks after the delivery of the second dosage, titers were obtained, overall, 45 Included individuals, of which 15 the medication was given to Pfizer-BioNTech vaccine, while 15 the medication was given to SinoPharm vaccine, 15 healthy group non-vaccinated, Remarkably, 15 (100 %) Among those vaccinated with the Pfizer-BioNTech vaccine Nucleocapsid IgG titers that Mean ± SD (49.451 ± 10.166), but Neutralizing IgG titer negative 15 (100 %) that Mean ± SD (0.241 ± 0.025) compared with control group that Mean ± SD (0.290 ± 0.046) at a probability level of (P≤0.01), while 15 (100 %) of SinoPharm recipients had positive Nucleocapsid IgG titers that Mean ± SD (99.141 ± 33.132), Neutralizing IgG titer Positive 15 (100 %) that Mean ± SD (0.972 ±0.308) compared with control group that Mean ± SD (0.290±0.046) at a probability level of (P≤0.01).

Keywords: SinoPharm-BBIBP-CorV, Pfizer-BioNTech and SARS-CoV-2 vaccine

1. Introduction

Even though the complications that are associated with It is straightforward to identify cases of elevated or uncontrolled cytokine and chemokine levels, It is still quite challenging to differentiate distinction between a healthy and a faulty cytokine response, This is because certain cytokines are absolutely necessary for the production of an efficient immune response, in order so that viral infections and other pathogens inside cells may be eliminated [1] more than 250 vaccine projects were started all over the world in the year 2020, and a large number of these projects entail active participation in preclinical testing on animals [2], A recent study WHO report stated that there are currently 97 clinical trials of vaccinations ranging from phases 1 to phases 3, the 182 vaccines Currently exist only in the pre-clinical phases of development [3,4]. A variety of technologies have been used in the preparation of vaccines, some of which are conventional while others are freshly developed and being used first time ever in human history [4], as of right now, at least 14 Clinical use of vaccinations is now possible or has been approved for use Anti- SARS-CoV-2 [3,5].

Vaccines against SARS-CoV-2 may induce simultaneous activation about the body's "innate" and "adaptive" immune systems, but our focus here is on adaptive immunity, which is mediated by the production of antibodies by B-cells that proportionally amplify and increase, causing the creation of antibodies that recognise and bind just the protein known as spike and prevent the virus from entering the cells and replicating, thereby immunity conferring to SARS-CoV-2 infection [6,7,8], Detection of the antibodies (IgG) to SARS-CoV-2 nucleocapsid (N), and spike (S) antigens is the basis for current serological diagnostic assays, which together create the immune memory that is the basis about vaccination efficacy [9].

Vaccines against SARS-CoV-2 had been created in order to stimulate the manufacturing of antibodies that are directed in comparison to the SARS-CoV-2 spike protein; currently, 2 families of vaccines have been implemented In order to prevent the propagation of SARS-CoV-2: mRNA vaccines, like those manufactured by Pfizer-BioNTech and traditional vaccinations that are inactivated, like those manufactured by Sinopharm. the immunologic monitoring carried out by the evaluation of levels of antibodies that are specific to antigens, allows us to partially explain vaccines and construct an effective vaccine strategy [12], the adaptive immunity to SARS-CoV-2 is anticipated IgG levels from anti-spike protein receptor-binding domain (anti-S-RBD), since these antibodies are the most effective form in guarding against the illness [8].

This research aims to purposed at contrasting the levels of protective antibodies in individuals who received the Pfizer-BioNTech vaccination to those who received the Sinopharm vaccine.

doi.org/10.31838/hiv22.02.662 Received: 29.04.22, Revised:11.05.22, Accepted: 17.08.22

2. Materials and Methods

The population that was sampled consisted of iraqi adults persons, who has received 2 doses of the SARS-CoV-2 vaccine from Pfizer-BioNTech or Sinopharm. These two dosages were given 21 days of separation for everyone of the patients who were included in the trial, and enrolment Throughout the course of the research that was performed eight weeks following the delivery with regard to the second dose, 30 peoples: 15 individuals who have received the Sinopharm vaccination and 15 people vaccinated with the Pfizer vaccine, two groups underwent the following tests: Nucleocapsid IgG and Neutralizing IgG, assessment of health and immune status, these assay employs the competitive inhibition enzyme immunoassay technique by Human ELISA device, Cusabio Kit made in USA.

3. Results

Different results were obtained between the two groups that we took (SinoPharm and Pfizer) and according to what is mentioned in the working methods, the concentrations of these interleukins were as shown in Table 1 and Figure 1,2

Table 1. Antibodies vaccinated and control group

	Vaccine type	Nucleocapsid(N)IgG	Neutralizing Ab. IgG	*P*-value
1	Sinopharm	99.141 ±33.132	0.972 ±0.308	P≤0.01
2	Pfizer	49.451 ±10.166	0.241 ±0.025	
3	Control	28.644±1.622	0.290±0.046	



Figure 1: Nucleocapsid IgG levels in Pfizer, Sionopharm and control



Figure 2: Neutralizing IgG Pfizer, Sionopharm and control

4. Discussion

This research shows that, we contrasted both the Nucleocapsid IgG antibody and Neutralizing IgG in Sinopharm and Pfizer vaccines in According to our best knowledge, this paper is the very first all-encompassing comparison of the adaptive immunity of these vaccinations in adult human volunteers.

The results of our current study shown in Table 1. and figure 1. showed a significant difference in the level of Nucleocapsid IgG between Pfizer and Sinopharm compared to the control group at a probability level of P≤0.01

As for the level of Neutralizing IgG in table 1. and figure 2., In contrast, there was a noticeable gap between Pfizer vaccine and Sinopharm vaccine compared to the control group at a probability level of P≤0.01.

The S domain referring to the spike protein of SARS-CoV-2 has been a primary focus of evaluation of vaccine-induced immune responses because Nucleocapsid IgG titres are greater after vaccination than after natural infection and serum from vaccinated person has higher in vitro neutralisation activity against SARS-CoV-2 homologs [13]; However, in spite of the fact that vaccination is known to induce strong the importance of T-cell responses for the provision of protection and vulnerability at the population level, independent of memory B cell responses, has been shown (Against a variety of viral epitopes, memory and effector activity have been shown), is not yet well understood [14, 15].

The findings of the present research are in line with those of other earlier publications like as [16], Incompatible alleles variants to a lesser or greater extent, of the HLA genes and other recognised genetic markers likely contribute to the observed striking Variations in the reactions of antibodies and T-cells among individuals across all experiments [17], The reduced total amount the immunodominant epitopes in the spike-only mRNA-vaccine vaccination in comparison to the inactivated SARS-CoV-2 may possibly account for the larger individual variances seen in the SinoPharm cohort as compared to Pfizer, This is due to the nature of the research undertaken from the time of the immunological measures, following the completion of the administration of second dosage, and two months after the implementation of the first dose, about three months, and this was stated by Tré-Hardy et al. [18] revealed the level of IgG-N to the Pfizer vaccine saw a considerable drop in three months, when relative to the extent that assessed at sixty days following the second vaccination dosage, the fall was due to about twofold [18], and this is referred to by Salvagno et al. [19], however, The inactivated viral vaccine elicits far wider antigenic reactions to membrane, nucleocapsid, and spike protein epitopes, but the mRNA vaccine only creates T cell reactions that precisely concentrating on the spike protein that is more likely to alterations, In other words, the Sinopharm vaccine, which targets several epitopes, in comparison to the Pfizer vaccine, may be able to considerably reduce the likelihood of immune evasion caused by new mutations. [20,21].

Conclusion

Since the levels of Nucleocapsid IgG and Neutralizing IgG in the SinoPharm vaccine were higher than in the Pfizer vaccine, those who have received all of their recommended vaccinations

against SinoPharm vaccine had superior quantitative efficiency, and a booster dose is supported for Pfizer-BioNTech recipients.

References

Fajgenbaum, D. C., & June, C. H. (2020). Cytokine storm. New England Journal of Medicine, 383(23), 2255-2273.

AL-Samarraie, M. Q., Mustafa, M. A., & Ahmed, M. T. .(2020). Management and treatment of COVID-19: A Review.Science Archives, 1 (3), 174-176. http://dx.doi.org/10.47587/SA.2020.1316.

Grun, G.C. COVID-19 Vaccine Development: What's the Progress? DW Agency, Updated on 12 May 2021. Available online: https://www.dw.com/en/covid-19-vaccine-development-whats-the-progress/a-55648707 (accessed on 20 May 2021)

8. WHO. Draft Landscape of COVID-19 Candidate Vaccines. Available online: https://www.who.int/publications/m/item/draftlandscape-of-covid-19-candidate-vaccines (accessed on 28 May 2021).

Abdulla, Z. A., Al-Bashir, S. M., Al-Salih, N. S., Aldamen, A. A., & Abdulazeez, M. Z. (2021). A summary of the SARS-CoV-2 vaccines and technologies available or under development. Pathogens, 10(7), 788.

Wu, Y.; Wang, F.; Shen, C.; Peng, W.; Li, D.; Zhao, C.; Li, Z.; Li, S.; Bi, Y.; Yang, Y.; et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 2020, 368, 1274–1278.

Mustafa, M. A., AL-Samarraie, M. Q., & Ahmed, M. T. (2020). Molecular techniques of viral diagnosis. Science Archives, 1(3), 89-92.

Lo Sasso, B.; Giglio, R.V.; Vidali, M.; Scazzone, C.; Bivona, G.; Gambino, C.M.; Ciaccio, A.M.; Agnello, L.; Ciaccio, M. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics 2021, 11, 1135.

Jacofsky, D.; Jacofsky, E.M.; Jacofsky, M. Understanding Antibody Testing for COVID-19. J. Arthroplast. 2020, 35, S74–S81.

Lo Sasso, B.; Gambino, C.M.; Scichilone, N.; Giglio, R.V.; Bivona, G.; Scazzone, C.; Muratore, R.; Milano, S.; Barbagallo, M.; Agnello, L.; et al. Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19. Lab Med. 2021, 52, 493–498.

Gambino, C.M.; Lo Sasso, B.; Colomba, C.; Giglio, R.V.; Agnello, L.; Bivona, G.; Ciaccio, M. Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG. Biochem. Med. 2020, 30, 030901

Adam, L.; Rosenbaum, P.; Bonduelle, O.; Combadière, B. Strategies for Immunomonitoring after Vaccination and during Infection. Vaccines 2021, 9, 365.

Grigoryan, L., & Pulendran, B. (2020, August). The immunology of SARS-CoV-2 infections and vaccines. In Seminars in immunology (Vol. 50, p. 101422). Academic Press.

Shrotri, M., van Schalkwyk, M. C., Post, N., Eddy, D., Huntley, C., Leeman, D., ... & Ismail, S. A. (2021). T cell response to SARS-CoV-2 infection in humans: A systematic review. PloS one, 16(1), e0245532.

Bertoletti, A., Tan, A. T., & Le Bert, N. (2021). The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunology, 2(1), iqab006.

Röltgen, K., & Boyd, S. D. (2021). Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host & Microbe, 29(7), 1063-1075.

Pojero, F., Candore, G., Caruso, C., Di Bona, D., Groneberg, D. A., Ligotti, M. E., ... & Aiello, A. (2021). The role of immunogenetics in COVID-19. International Journal of Molecular Sciences, 22(5), 2636.

Tré-Hardy, M., Cupaiolo, R., Wilmet, A., Beukinga, I., & Blairon, L. (2021). Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers. Journal of Infection, 83(3), 381-412.

Salvagno, G. L., Henry, B. M., Pighi, L., De Nitto, S., Gianfilippi, G. L., & Lippi, G. (2021). Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers. Journal of Infection, 83(2), e4-e5.

Cohen, K. W., Linderman, S. L., Moodie, Z., Czartoski, J., Lai, L., Mantus, G., ... & McElrath, M. J. (2021). Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Reports Medicine, 2(7), 100354.

Matchett, W. E., Joag, V., Stolley, J. M., Shepherd, F. K., Quarnstrom, C. F., Mickelson, C. K., ... & Masopust, D. (2021). Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. The Journal of Immunology, 207(2), 376-379.